Vaccines worries hit GSK

GSK PLC reported Q3 sales of £8.9B, beating expectations, with core EPS of 54.6p. Shares fell 4% due to weaker vaccine sales and a cautious profit outlook. GSK reaffirmed 2026 guidance but expects EPS growth in the lower half of its 7%-9% range. Jefferies rates GSK 'buy' with a 2,500p target.

Original reporting
Published Oct 28, 2026, 8:59 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 9:21 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Vaccines worries hit GSK — source image
Decision brief

The 30-second read

$GSKBearishHigh
01

Why it matters

The miss in vaccine revenue drove a 4% share decline despite overall earnings beat, highlighting the segment's weight in investor expectations.

02

Market read

First‑report earnings for a large‑cap pharma; immediate price impact makes it a high‑value trading signal.

03

What to watch

Lower tax rate and higher royalty income may offset vaccine weakness in the longer term.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

GSK's Q3 earnings were released, showing core operating profit up 5% and EPS beat, but vaccine sales fell short of forecasts.

Company-level read

Ticker impact

$GSKBearishHigh confidence
Context

GSK reported Q3 results that beat forecasts but vaccine sales missed expectations, causing the stock to fall 4% in early trading.

Expected impact

downward pressure as investors price in lower vaccine sales

Evidence & confidence

The earnings release is the first report of the miss; the 4% drop shows immediate market reaction.

Market effects

Vaccine and broader pharma sector may face scrutiny over sales momentum.

UK‑listed pharma stocks could see similar pressure.

Large‑cap pharma earnings influence global health‑care indices.

Counterpoint

The earnings beat and strong core profit margin could support a rebound if vaccine outlook improves.

Key entities

  • GSK PLC

    British pharmaceutical giant listed in the US as GSK.

Related articles

$LLYMedAI 8/10

Rx Rundown: Ollin Biosciences, AstraZeneca, Isomorphic Labs and more

Eli Lilly, AbbVie, Johnson & Johnson, and others announced major deals and acquisitions in the biopharma sector, totaling billions. AstraZeneca, Roche, and Novo Nordisk received FDA approvals for new treatments. Isomorphic Labs raised $5 billion in private financing. AstraZeneca cut 600 jobs, while Cellectis plans to cut 70% of its workforce.

$GSKMed

Nelkarmi gives ALK-positive lung cancer patients a new option after first-line therapy stops working

GSK's Nelkarmi (neladalkib) received FDA accelerated approval for ALK-positive NSCLC patients after prior ALK therapy. Approval based on ALKOVE-1 trial showing 49% tumor shrinkage in Alecensa-only group. GSK acquired Nelkarmi via Nuvalent acquisition. Continued approval contingent on confirmatory trial. ALKAZAR phase 3 trial ongoing for first-line treatment.

$GSKMedAI 8/10

GSK’s $10.6bn Nuvalent bet pays off with second lung cancer drug approval

GSK's Nelkarmi (neladalkib) received FDA approval for treating ALK-positive non-small cell lung cancer, the second drug from its $10.6bn Nuvalent acquisition. The approval was based on trial results showing a 49% response rate. GSK expects significant sales, with forecasts predicting $1.2bn by 2032. Roche's Alecensa is a key competitor. Approval hinges on ongoing Phase III trial results.

$GSKMed

GSK Wins Second Lung Cancer Approval of 2026 as FDA Clears Nelkarmi — BigGo Finance

GSK (GSK) received FDA approval for Nelkarmi, a lung cancer drug, based on Phase 1/2 trial data. The drug targets ALK gene mutations and showed activity against brain metastases. GSK acquired Nelkarmi through its $10.6B Nuvalent deal. Analysts project $1B in 2032 sales, with peak sales estimates of $5B-$7B for GSK's lead Nuvalent drugs. The approval is seen as a validation of GSK's oncology portfolio strategy.